Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

由 Dusselier, Matthieu, Deluche, Elise, Delacourt, Nellie, Ballouhey, Julia, Egenod, Thomas, Melloni, Boris, Vergnenègre, Charlotte, Veillon, Rémi, Vergnenègre, Alain
發表在 PLoS One (2019)